S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.57
+1.89
+11.33%
CRBP · Corbus Pharmaceuticals Holdings, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Corbus Pharmaceuticals Holdings Inc (CRBP)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$4.29
-0.12
(-2.83%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.29
$4.28
$4.53
52-WEEK RANGE
$4.29
$4.22
$20.56
What's happening
- CRBP is down 2.83% today, trading at $4.29. — Live quote
- It's trading within 3% of its 52-week low ($4.22). (Finnhub fundamentals)
- Volume today (21,606) is well below its 3-month average of 719,590. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.81 actual vs. $-1.28 estimated (-41.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CRBP
-45.70%
vs S&P 500
-58.48%
1-YEAR RETURN
CRBP
-75.82%
vs S&P 500
-90.38%
6-MONTH RETURN
CRBP
-56.41%
3-MONTH RETURN
CRBP
-50.78%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.81
Est. $-1.28
MISS -41.1%
2026-04-26 (Q1 2026)
$-1.23
Est. $-1.24
BEAT +1.2%
2026-01-26 (Q4 2025)
$-1.25
Est. $-1.61
BEAT +22.2%
2025-10-26 (Q3 2025)
$-1.90
Est. $-1.74
MISS -9.1%
Valuation Measures & Ratios
Enterprise Value4$66.2M
Forward P/E5—
PEG Ratio6-0.02
Price / Sales (TTM1)57.77
Price / Book71.70
EV4 / Revenue42.70
EV4 / EBITDA—
Profit Margin-2838.71%
Operating Margin-4309.68%
Return on Equity (ROE8)-87.05%
Return on Assets (ROA9)-74.22%
Avg Volume (3M)719,590
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $181.9M | $175.2M | $156.5M | $85.1M | $64.9M |
| P/E | -1.84 | -2.16 | -2.18 | -1.46 | -1.36 |
| Price/Book | 1.78 | 1.39 | 1.70 | 0.77 | 0.51 |
| ROE | -96.84% | -64.07% | -77.88% | -52.63% | -37.49% |
| ROA | -77.97% | -56.03% | -65.53% | -46.70% | -34.06% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,054,964
Change from Prior Settlement+10.72%
% of Float—
Days to Cover (Short Ratio)3.86
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -2838.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -75.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CRBP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$36.2M | -$24.3M | -$24.4M | -$19.2M | -$19.8M | -$15.5M | -$11.0M | -$9.6M |
| Net income | -$35.0M | -$23.0M | -$23.3M | -$17.7M | -$17.0M | -$13.8M | -$10.0M | -$6.9M |
| EPS (diluted) | $-1.81 | $-1.23 | $-1.90 | $-1.44 | $-1.39 | $-1.15 | $-0.90 | $-0.83 |
| EPS (basic) | $-1.81 | $-1.23 | $-1.90 | $-1.44 | $-1.39 | $-1.15 | $-0.90 | $-0.83 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $127.0M | $144.5M | $168.2M | $109.5M | $125.1M | $139.9M | $155.9M | $164.2M |
| Total liabilities | $24.7M | $18.1M | $20.7M | $17.4M | $14.1M | $12.8M | $13.5M | $13.7M |
| Stockholders' equity | $102.2M | $126.3M | $147.5M | $92.1M | $111.0M | $127.1M | $142.4M | $150.5M |
| Total current assets | $122.8M | $143.6M | $167.0M | $107.6M | $122.8M | $137.4M | $153.0M | $160.9M |
| Total current liabilities | $21.5M | $18.1M | $20.7M | $17.1M | $13.3M | $11.6M | $11.8M | $11.6M |
| Cash & equivalents | $23.4M | $25.7M | $28.5M | $27.0M | $20.0M | $18.9M | $17.2M | $19.4M |
| Marketable securities (current) | $94.6M | $112.6M | $134.8M | $77.0M | $96.5M | $113.9M | $131.9M | $139.9M |
| Property, plant & equipment | $71.0K | $116.0K | $159.0K | $201.0K | $251.0K | $304.0K | $385.0K | $519.0K |
| Other non-current assets | — | — | — | — | — | — | $0 | $0 |
| Accounts payable | $5.3M | $435.0K | $2.2M | $2.7M | $4.0M | $4.1M | $4.8M | $2.9M |
| Accrued liabilities | $15.2M | $16.5M | $16.8M | $12.6M | $7.7M | $5.9M | $5.4M | $7.2M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | $0 | $0 |
| Common stock & paid-in capital | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained earnings | -$613.4M | -$578.4M | -$555.4M | -$534.9M | -$511.5M | -$493.9M | -$476.9M | -$467.4M |
| Accumulated other comprehensive income (loss) | -$107.0K | -$161.0K | -$53.0K | -$3.0K | -$39.0K | -$23.0K | $35.0K | $207.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.6M | -$25.6M | -$15.9M | -$15.6M | -$16.6M | -$16.4M | -$10.9M | -$13.9M |
| Investing cash flow | $18.3M | $22.5M | -$57.1M | $19.6M | $17.7M | $18.1M | $8.7M | -$15.4M |
| Financing cash flow | $9.1M | — | $74.6M | $2.9M | $0 | $0 | -$13.0K | $25.0M |
| Free cash flow | -$29.6M | -$25.6M | -$15.9M | — | -$16.6M | -$16.4M | -$10.9M | — |
| Capital expenditures | $6.0K | $6.0K | $7.0K | — | $0 | $0 | $0 | — |
| Share-based compensation | $1.8M | $1.9M | $1.4M | $1.6M | $1.6M | $1.7M | $1.6M | $2.2M |
| Change in accounts payable | $4.8M | -$1.9M | -$564.0K | -$1.3M | $175.0K | -$684.0K | $1.7M | $2.0M |
| Purchases of investments | $8.7M | $10.7M | $90.0M | $17.8M | $17.6M | $37.6M | $11.2M | $38.8M |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $881.7K |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$39.8M | -$56.0M |
| Net income | -$78.5M | -$40.2M | -$44.6M | -$42.3M | -$45.6M |
| EPS (diluted) | $-5.90 | $-3.68 | $-10.31 | $-10.15 | $-11.15 |
| EPS (basic) | $-5.90 | $-3.68 | $-10.31 | $-10.15 | $-11.15 |
| Operating margin | — | — | — | — | -$6.4K |
| Net margin | — | — | — | — | -$5.2K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $168.2M | $155.9M | $28.3M | $66.3M | $107.7M |
| Total liabilities | $20.7M | $13.5M | $35.2M | $33.3M | $38.6M |
| Stockholders' equity | $147.5M | $142.4M | -$6.9M | $33.0M | $69.1M |
| Total current assets | $167.0M | $153.0M | $23.5M | $60.2M | $100.2M |
| Total current liabilities | $20.7M | $11.8M | $31.9M | $12.6M | $17.0M |
| Cash & equivalents | $28.5M | $17.2M | $13.7M | $17.0M | $25.0M |
| Marketable securities (current) | $134.8M | $131.9M | $7.2M | $42.2M | $72.6M |
| Property, plant & equipment | $159.0K | $385.0K | $973.0K | $1.6M | $2.4M |
| Other non-current assets | — | $0 | $212.0K | $155.3K | $46.4K |
| Accounts payable | $2.2M | $4.8M | $3.2M | $2.2M | $1.8M |
| Accrued liabilities | $16.8M | $5.4M | $11.0M | $6.0M | $10.1M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | $15.9M | $2.8M | $3.1M |
| Long-term debt | — | — | $0 | $16.0M | $15.6M |
| Other non-current liabilities | — | $0 | $44.0K | $22.2K | $22.2K |
| Common stock & paid-in capital | $2.0K | $1.0K | $0 | $417 | $416 |
| Retained earnings | -$555.4M | -$476.9M | -$436.7M | -$392.1M | -$349.7M |
| Accumulated other comprehensive income (loss) | -$53.0K | $35.0K | -$1.0K | -$126.1K | -$62.4K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.5M | -$48.2M |
| Investing cash flow | -$1.6M | -$121.3M | $35.6M | $30.1M | -$73.4M |
| Financing cash flow | $77.4M | $166.6M | -$2.8M | -$533.6K | $60.8M |
| Free cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.6M | -$48.2M |
| Capital expenditures | $7.0K | $0 | $0 | $13.4K | $54.2K |
| Share-based compensation | $6.3M | $6.1M | $3.5M | $5.7M | $9.5M |
| Change in accounts payable | -$2.3M | $1.6M | $1.0M | -$256.8K | -$6.0M |
| Purchases of investments | $163.1M | $180.8M | $33.9M | $86.3M | $87.3M |
| Debt issued | — | — | — | $1.4M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CRBP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers65.8%
Shares Outstanding19,407,688
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,344,971 | $22.0M | 12.08% | +0.0% | 2026-08-14 |
| ORBIMED ADVISORS LLC | 1,737,287 | $16.3M | 8.95% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 1,331,135 | $12.5M | 6.86% | +390.0% | 2026-08-07 |
| Aberdeen Group plc | 1,321,750 | $12.4M | 6.81% | +0.0% | 2026-07-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 760,940 | $7.1M | 3.92% | +3.7% | 2026-06-30 |
| Jones Hill Capital LP | 653,572 | $6.1M | 3.37% | +0.0% | 2026-08-13 |
| Prosight Management, LP | 650,000 | $6.1M | 3.35% | +0.0% | 2026-08-14 |
| Stonepine Capital Management, LLC | 425,000 | $4.0M | 2.19% | +10.8% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 423,374 | $4.0M | 2.18% | +126.4% | 2026-08-12 |
| ADAR1 Capital Management, LLC | 421,787 | $4.0M | 2.17% | +27.1% | 2026-08-14 |
| DIADEMA PARTNERS LP | 301,264 | $2.8M | 1.55% | -31.5% | 2026-08-14 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 293,203 | $2.8M | 1.51% | -12.1% | 2026-08-14 |
| State Street Corp | 254,672 | $2.4M | 1.31% | +269.8% | 2026-08-07 |
| DIMENSIONAL FUND ADVISORS LP | 190,214 | $1.8M | 0.98% | +39.2% | 2026-08-11 |
| Exome Asset Management LLC | 184,914 | $1.7M | 0.95% | -21.0% | 2026-08-14 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 151,640 | $1.4M | 0.78% | -5.5% | 2026-08-14 |
| JANE STREET GROUP, LLC | 139,133 | $1.3M | 0.72% | +90.1% | 2026-08-14 |
| Northern Trust Corp | 124,906 | $1.2M | 0.64% | +200.9% | 2026-08-12 |
| VANGUARD FIDUCIARY TRUST CO | 112,397 | $1.1M | 0.58% | +16.8% | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 111,302 | $1.0M | 0.57% | +356.8% | 2026-06-30 |
| RENAISSANCE TECHNOLOGIES LLC | 110,822 | $1.0M | 0.57% | -68.1% | 2026-08-13 |
| DAFNA Capital Management LLC | 107,773 | $1.0M | 0.56% | +0.0% | 2026-08-14 |
| CITADEL ADVISORS LLC | 92,154 | $864.4K | 0.47% | -87.3% | 2026-08-14 |
| Advisory Services Network, LLC | 89,951 | $843.7K | 0.46% | +642407.1% | 2026-08-12 |
| MARSHALL WACE, LLP | 79,331 | $744.1K | 0.41% | -45.9% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-14 to 2026-09-14
Recent transactions
- Insiders have net sold 24,138 shares over the last 182 days, across 3 purchases and 6 sales.
- Most recent: Ben Yong (Reporting person) — Open market sale of 2,000 shares on 2026-09-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)16,100 sh(3 txns)
Sales (open market)40,238 sh(6 txns)
Net Shares-24,138
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Ben Yong | Reporting person | Open market sale | 2026-09-14 | 2,000 |
| Nicacio Leonardo Viana | Chief Medical Officer | Grant / award | 2026-08-16 | 58,333 |
| Saxena Nishant C | Chief Business Officer | Open market purchase | 2026-08-11 | 2,600 |
| Cohen Yuval | Chief Executive Officer | Open market sale | 2026-08-07 | 17,000 |
| Moran Sean F. | Chief Financial Officer | Open market sale | 2026-08-07 | 12,000 |
| Kung Winston | Reporting person | Open market sale | 2026-06-10 | 2,026 |
| Altmeyer Anne | Reporting person | Open market sale | 2026-06-10 | 2,412 |
| Jenkins John Kenneth | Reporting person | Open market sale | 2026-06-10 | 4,800 |
| Jacques Rachelle Suzanne | Reporting person | Grant / award | 2026-05-19 | 3,800 |
| Pfeiffenberger Brent | Reporting person | Grant / award | 2026-05-19 | 7,500 |
| Smethurst Dominic | Chief Medical Officer | Open market sale | 2026-03-02 | 6,097 |
| Hodgson Ian | Chief Operating Officer | Open market sale | 2026-02-17 | 847 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Ben Yong | Reporting person | Open market sale | 2,000 | $7.84 |
| 2026-08-16 | Nicacio Leonardo Viana | Chief Medical Officer | Grant / award | 58,333 | $0.00 |
| 2026-08-11 | Saxena Nishant C | Chief Business Officer | Open market purchase | 2,600 | $9.63 |
| 2026-08-07 | Cohen Yuval | Chief Executive Officer | Open market sale | 17,000 | $10.08 |
| 2026-08-07 | Moran Sean F. | Chief Financial Officer | Open market sale | 12,000 | $10.08 |
| 2026-06-10 | Kung Winston | Reporting person | Open market sale | 2,026 | $7.91 |
| 2026-06-10 | Altmeyer Anne | Reporting person | Open market sale | 2,412 | $7.91 |
| 2026-06-10 | Jenkins John Kenneth | Reporting person | Open market sale | 4,800 | $7.91 |
| 2026-06-03 | Saxena Nishant C | Chief Business Officer | Open market purchase | 9,000 | $7.58 |
| 2026-06-02 | Saxena Nishant C | Chief Business Officer | Open market purchase | 4,500 | $7.33 |
| 2026-05-21 | Saxena Nishant C | Chief Business Officer | Grant / award | 58,300 | $0.00 |
| 2026-05-19 | Kung Winston | Reporting person | Grant / award | 3,800 | $0.00 |
| 2026-05-19 | Jacques Rachelle Suzanne | Reporting person | Grant / award | 3,800 | $0.00 |
| 2026-05-19 | Jenkins John Kenneth | Reporting person | Grant / award | 3,800 | $0.00 |
| 2026-05-19 | Altmeyer Anne | Reporting person | Grant / award | 3,800 | $0.00 |
| 2026-05-19 | Ben Yong | Reporting person | Grant / award | 3,800 | $0.00 |
| 2026-05-19 | Pfeiffenberger Brent | Reporting person | Grant / award | 7,500 | $0.00 |
| 2026-03-02 | Smethurst Dominic | Chief Medical Officer | Open market sale | 6,097 | $8.30 |
| 2026-02-17 | Hodgson Ian | Chief Operating Officer | Open market sale | 847 | $7.38 |
| 2026-02-13 | Moran Sean F. | Chief Financial Officer | Open market sale | 4,701 | $7.78 |
| 2026-02-13 | Cohen Yuval | Chief Executive Officer | Open market sale | 13,871 | $7.78 |
| 2026-02-03 | Smethurst Dominic | Chief Medical Officer | Open market sale | 3,285 | $8.09 |
| 2026-02-03 | Hodgson Ian | Chief Operating Officer | Open market sale | 2,415 | $8.09 |
| 2026-01-14 | Smethurst Dominic | Chief Medical Officer | Grant / award | 28,365 | $0.00 |
| 2026-01-14 | Moran Sean F. | Chief Financial Officer | Grant / award | 28,082 | $0.00 |
| 2026-01-14 | Cohen Yuval | Chief Executive Officer | Grant / award | 50,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:07 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-16 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-06 | 8-K | 2026-07-02 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-10 | View on SEC.gov → |
Recent news
Headlines about CRBP (Corbus Pharmaceuticals Holdings, Inc.). Links open the publisher — we don’t host full articles.
-
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
MarketWatch · 2026-10-19 -
CRBP Q2 2026 Earnings: Wider-Than-Expected Loss Draws Modest Positive Share Reaction - EPS Miss Report
https://www.dars.gov.et/ · 2026-10-16 -
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
MarketWatch · 2026-10-16 -
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
MarketWatch · 2026-10-15 -
A throat cancer trial doses its first patient as Corbus (CRBP) reports CRB-701 response data.
Stock Titan · 2026-10-15 -
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Yahoo Finance · 2026-09-29 -
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy - Slideshow
Seeking Alpha · 2026-09-17 -
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
Yahoo Finance · 2026-09-15
No headlines in this category right now — try “All”.